Vaccines for preventing cholera: killed whole cell or other subunit vaccines (injected)

Cochrane Database of Systematic Reviews

Volumn 2019, Issue 5, 2010, Pages

  Graves, Patricia M ^a   Deeks, Jonathan J ^b   Demicheli, Vittorio ^c   Jefferson, Tom ^d  

^a CARTER CENTER   (United States)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c SSEpi SeREMI Cochrane Vaccines Field   (Italy)

^d Vaccines Field   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA VACCINE; INACTIVATED VACCINE;

ADULT; CHILD; CHOLERA; HUMAN; IMMUNOLOGY; INFANT; INJECTION; META ANALYSIS; METHODOLOGY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; REVIEW; VACCINATION;

ADULT; CHILD; CHILD, PRESCHOOL; CHOLERA; CHOLERA VACCINES; HUMANS; INFANT; INJECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINATION; VACCINES, INACTIVATED;

EID: 77955941435     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD000974.pub2     Document Type: Review

References (71)

1. Azurin JC. A controlled field trial on the effectiveness of cholera and cholera el Tor vaccines in the Phillipines. Proceedings of the Cholera Research Symposium. 1965:369-73.
2. Azurin JC, Alvero M. Cholera incidence in a population offered cholera vaccination: comparison of cooperative and uncooperative groups. Bulletin of the World Health Organization 1971;44(6):815-9.
3. Azurin JC, Cruz A, Pesigan TP, Alvero M, Camena T, Suplido R, Ledesma L, Gomez CZ. A controlled field trial of the effectiveness of cholera and cholera el Tor vaccines in the Phillipines. Bulletin of the World Health Organization 1967;37(5):703-27.
4. [No authors listed]. A controlled field trial of the effectiveness of cholera and cholera el Tor vaccines in the Phillipines. Preliminary report; Phillipines Cholera Committee. Bulletin of the World Health Organization 1965;32(5):603-25.
5. See Azurin 1965i.
6. See Azurin 1965i.
7. Benenson AS, Joseph PR, Oseasohn RO. Cholera vaccine field trials in East Pakistan. 1. Reaction and antigenicity studies. Bulletin of the World Health Organization 1968;38(3):347-57.
8. Benenson A, Mosley WH, Fahimuddin M, Oseasohn RO. Cholera vaccine field trials in East Pakistan. 2. Effectiveness in the field. Bulletin of the World Health Organization 1968;38(3):359-72.
9. Mosley WH, Benenson AS, Barui R. A serological survey for cholera antibodies in rural east Pakistan 2. A comparison of antibody titres in the immunized and control populations of a cholera-vaccine field trial area and the relation of antibody titre to cholera case rate. Bulletin of the World Health Organization 1968;38(3):335-46.
10. See Benenson 1968-i.
11. Burgasov PN, Sumarokov AA, Lelikov VL, Marcuk LM, Fedenev VG, Dzaparidze MN, et al. Comparative study of reactions and serological response to cholera vaccines in a controlled field trial conducted in the USSR. Bulletin of the World Health Organization 1976;54(2):163-70.
12. Curlin G, Levine M, Aziz KMA, Mizanur Rahman ASM, Verwey WF. Field trial of cholera toxoid. Proceedings of the eleventh joint conference on cholera. New Orleans: US-Japan Cooperative Medical Science Program, 1975 Nov:314-29.
13. Curlin GT, Levine RJ, Ahmed A, Aziz KMA, Mizanur Rahman ASM, Verwey WF. Immunological aspects of a cholera toxoid field trial in Bangladesh. Dacca: Cholera Research Laboratory, 1978 March. Scientific Report No. 8.
14. das Gupta A, Sinha R, Shrivastava DL, De SP, Taneja BL, Rao MS, et al. Controlled field trial of the effectiveness of cholera and cholera el tor vaccines in Calcutta. Bulletin of the World Health Organization 1967;37(5):371-85.
15. das Gupta A, Sinha R, Shrivastava DL, De SP, Taneja BL, Rao MS, et al. Controlled field trial of the effectiveness of cholera and cholera El Tor vaccines in Calcutta. Bulletin of the World Health Organization 1967;37(5):371-85.
16. See das Gupta A 1965b-i.
17. McCormack WM, Rahman ASMM, Chowdhury AKMA, Mosley WH, Phillips RA. Report of the 1966-67 cholera vaccine trial in rural East Pakistan 3. The lack of effect of prior vaccination or circulating vibriocidal antibody on the severity of clinical cholera. Bulletin of the World Health Organization 1969;40(2):199-204.
18. Mosley WH, Aziz KMA, Rahman ASMM, Chowdhury AKMA, Ahmed A, Fahimuddin M. Report of the 1966-67 cholera vaccine trial in rural East Pakistan. 4. Five years of observation with a practical assessment of the role of a cholera vaccine in cholera control programmes. Bulletin of the World Health Organization 1972;47(2):229-38.
19. Mosley WH, McCormack WM, Ahmed A, Chowdhury AKMA, Barui RK. Report of the 1966-67 cholera vaccine field trial in rural East Pakistan. 2. Results of the serological surveys in the study population--the relationship of case rate to antibody titre and an estimate of the inapparent infection rate with Vibrio cholerae. Bulletin of the World Health Organization 1969;40(2):187-97.
20. Mosley WH, McCormack WM, Fahimuddin M, Aziz KM, Rahman AS, Chowdhury AK, et al. Report of the 1966-67 cholera vaccine field trial in rural East Pakistan. I. Study design and results of the first year of observation. Bulletin of the World Health Organization 1969;40(2):177-85.
21. Mosley WH, Aziz KM, Rahman AS, Chowdhury AK, Ahmed A. Field trials of monovalent Ogawa and Inaba cholera vaccines in rural Bangladesh--three years of observation. Bulletin of the World Health Organization 1973;49(4):381-7.
22. Mosley WH, Woodward WE, Aziz KM, Rahman AS, Chowdhury AK, Ahmed A, et al. The 1968-1969 cholera-vaccine field trial in rural East Pakistan. Effectiveness of monovalent Ogawa and Inaba vaccines and a purified Inaba antigen, with comparative results of serological and animal protection tests. Journal of Infectious Diseases 1970;121 Suppl:1-9.
23. See Mosley 1970-i.
24. See Mosley 1970-i.
25. Benenson A, Mosley WH, Fahimuddin M, Oseasohn RO. Cholera vaccine field trials in East Pakistan. 2. Effectiveness in the field. Bulletin of the World Health Organization 1968;38(3):359-72.
26. Mosley WH, Benenson AS, Barui R. A serological survey for cholera antibodies in rural east Pakistan. 2. A comparison of antibody titres in the immunized and control population of a cholera-vaccine field-trial area and the relation of antibody titre to cholera case rate. Bulletin of the World Health Organization 1968;38(3):335-46.
27. Oseasohn RO, Benenson AS, Fahimuddin M. Cholera vaccine field trial in rural East Pakistan (first year of observation). Proceedings of the Cholera Research Symposium; 1965; Honolulu. 1965:362-6.
28. Pal SC, Deb BC, Sen Gupta PG, De SP, Sircar BK, Sen D, et al. A controlled field trial of an aluminium phosphate-adsorbed cholera vaccine in Calcutta. Bulletin of the World Health Organization 1980;58(5):741-5.
29. Philippines Cholera Committee. A controlled field trial of the effectiveness of various doses of cholera el Tor vaccine in the Philippines. Bulletin of the World Health Organization 1968;38(6):917-23.
30. Philippines Cholera Committee. A controlled field trial of the effectiveness of monovalent classical and el tor cholera vaccines in the Philippines. Bulletin of the World Health Organization 1973;49(1):13-9.
31. See PCC 1973b-i.
32. See PCC 1973b-i.
33. See PCC 1973b-i.
34. Philippines Cholera Committee. A controlled field trial on the effectiveness of the intradermal and subcutaneous administration of cholera vaccine in the Philippines. Bulletin of the World Health Organization 1973;49(4):389-94.
35. Saroso JS, Bahrawi W, Witjaksono H, Budiarso RL, Brotowasisto, Bencić Z, et al. A controlled field trial of plain and aluminium hydroxide-adsorbed cholera vaccines in Surabaya, Indonesia, during 1973--75. Bulletin of the World Health Organization 1978;56(4):619-27.
36. See Saroso 1978i.
37. Taneja BL. Controlled field trials of cholera vaccines in Calcutta. Proceedings of the Cholera Research Symposium. 1965:373-379.
38. das Gupta A, Sinha R, Shrivastava DL, De SP, Taneja BL, Rao MS, Abou-Gareeb AH. Controlled field trial of the effectiveness of cholera and cholera el tor vaccines in Calcutta. Bulletin of the World Health Organization 1967;37(5):371-385.
39. Beran GW, Elvina O, Florendo FN Jr. Studies on the role of active immunization in the prevention of cholera El Tor. Journal of the Philippine Medical Association 1964;40(2):122-35.
40. Beran GW, Elviña O, Florendo FN Jr. Human volunteer studies using el tor cholera vaccines. I. Post-vaccinal reactions. Journal of the Philippine Medical Association 1965;41(3):183-90.
41. Black RE, Yunus MD, Eusof A, Ahmed A, Khan MR, Sack DA. Report on reactogenicity and immunogenicity of Wellcome cholera toxoids in Bangladeshi volunteers. Dacca, Bangladesh: International Centre for Diarrhoeal Disease Research, 1979 July. Scientific Report No. 29.
42. Cabrera O, Martínez ME, Cuello M, Soto CR, Valmaseda T, Cedré B, et al. Preparation and evaluation of vibrio cholerae O1 EL Tor Ogawa lipopolysaccharide-tetanus toxoid conjugates. Vaccine 2006;2006(24 Suppl 2):74-5.
43. Chandra Sekar C. Statistical assessment if the efficacy of anticholera inoculation from the data of 63 cheris in South Arcot district. Indian Journal of Medical Research 1947;35(3):153-76.
44. Clasener HA, Beunders BJ. Immunization of man with typhoid and cholera vaccine. Agglutinating antibodies after intracutaneous and subcutaneous injection. Acta Leidensia 1968;36:78-85.
45. Ganguly R, Clem LW, Bencic Z, Sinha R, Sakazaki R, Waldman RH. Antibody response in the intestinal secretions of volunteers immunized with various cholera vaccines. Bulletin of the World Health Organization 1975;52(3):323-30.
46. Gateff C, Dodin A, Wiart J. A comparison of the serological effects of classical cholera vaccine and of purified fraction vaccine, with or without simultaneous yellow fever vaccine (author's transl). Annales de Microbiologie 1975;126(2):231-46.
47. Gupta RK, Taylor DN, Bryla DA, Robbins JB, Szu SC. Phase 1 evaluation of Vibrio cholerae 01, serotype Inaba, polysaccharide-cholera toxin conjugates in adult volunteers. Infection and Immunity 1998;66(7):3095-9.
48. McBean AM, Agle AN, Compaore P, Foster SO, McCormack WM. Comparison of intradermal and subcutaneous routes of cholera vaccine administration. Lancet 1972;1(7749):527-9.
49. Mosley WH, Benenson AS, Barui R. A serological survey for cholera antibodies in rural east Pakistan. 1. The distribution of antibody in the control population of a cholera-vaccine field-trial area and the relation of antibody titre to the pattern of endemic cholera. Bulletin of the World Health Organization 1968;38(3):327-34.
50. Nimbkar YS, Karbhari RS, Cherian S, Chanderkar NG, Bhamaria RP, Ranadive PS, et al. Antibody response to two cholera vaccines in volunteers. Progress in Drug Research 1975;19:544-62.
51. Peltola H, Ruutu P, Palomäki H, Kaukinen K, Aho K. Intracutaneous vaccination technic with less side effects against typhoid and cholera. Duodecim 1977;93(7):431-8.
52. Russell AJH. Bezredka's cholera bilivaccin versus anti-cholera vaccine: a comparative field test. Transactions of the seventh congress of the Far East Association of Tropical Medicine 1927;1:523-34.
53. Sommer A, Khan M, Mosley WH. Efficacy of vaccination of family contacts of cholera cases. Lancet 1973;1(7814):1230-2.
54. Abba K, Qadri F, Graves PM, Zaman K. Oral vaccines for preventing cholera. Cochrane Database of Systematic Reviews In progress.
55. Bhadra RK, Dasgupta U, Das J. Cholera vaccine: developmental strategies and problems. Indian Journal of Biochemistry and Biophysics 1994;31(6):441-8.
56. Calain P, Chaine JP, Johnson E, Hawley ML, O'Leary MJ, Oshitani H, et al. Can oral cholera vaccination play a role in controlling a cholera outbreak?. Vaccine 2004;22(19):2444-51.
57. Clemens J, Spriggs D, Sack D. Public health considerations for the use of cholera vaccines in cholera control programes. In: Wachsmuth K, Blake PA, Olvik O editor(s). Vibrio cholerae and cholera: molecular to global perspectives. Washington: American Society for Microbiology, 1994:25-40.
58. Clemens J, Brenner R, Rao M, Tafari N, Lowe C. Evaluating new vaccines for developing countries. Efficacy or effectiveness?. JAMA 1996;275(5):390-7.
59. Cvjetanović B, Grab B, Uemura K. Dynamics of acute bacterial diseases. Epidemiological models and their application in public health. Part I. Theory and practice of epidemiological models. Bulletin of the World Health Organization 1978;56 Suppl 1:9-23.
60. Cvjetanović B, Grab B, Uemura K. Dynamics of acute bacterial diseases. Epidemiological models and their application in public health. Part II. Epidemiological models of acute bacterial diseases. Bulletin of the World Health Organization 1978;56 Suppl 1:25-143.
61. Davis R, Spencer CM. Live oral cholera vaccine: A preliminary review of its pharmacology and clinical potential in providing protective immunity against cholera. Clinical Immunotherapeutics 1995;4(3):235-47.
62. Feeley JC, Gangarosa EJ. Field trials of Cholera vaccine [Cholera and related diarrheas]. 43rd Nobel symposium; 1978; Stockholm, Sweden. Basel: Karger, 1980:204-10.
63. Graves PM, Deeks JJ, Demicheli V, Pratt M, Jefferson T. Vaccines for preventing cholera. Cochrane Database of Systematic Reviews 2001, Issue 1. [DOI: 10.1002/14651858.CD000974]
64. Jefferson T, Jefferson V. The quest for trials on the efficacy of human vaccines. Results of the handsearch of Vaccine. Vaccine 1996;14(6):461-4.
65. Jefferson T. Vaccine trial data systematically assembled, pooled and disseminated by the Cochrane Collaboration. Vaccine 1998;16(16):1487-95.
66. Joo I. Cholera vaccines. In: Barua D, Burrows W editor(s). Cholera. Philadelphia: Saunders, 1974:333-5.
67. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org (accessed 1 September 2008).
68. Sommer A, Mosley WH. Ineffectiveness of cholera vaccination as an epidemic control measure. Lancet 1973;814:1232-5.
69. Sánchez JL, Taylor DN. Cholera. Lancet 1997;349(9068):1825-30.
70. WHO. Cholera, 2005. Weekly Epidemiological Record 2006;81:297-308.
71. World Health Organization, Global Task Force on Cholera Control. Oral cholera vaccine use in complex emergencies: what next? Report of a WHO meeting, 14-16 December 2005, Cairo, Egypt [WHO/CDS/NTD/IDM/2006.2]. Geneva: World Health Organization, 2006.